💊 UK’s NICE approves a $3 billion treatment; More bad news for Biogen; Cipla acquires more green energy stakes; Is Sanofi’s $11 billion bet beginning to pay off?

Feb 07, 2022

∙ Paid

Hello and welcome to another exciting week. Wait, you don’t think the week’s going to be exciting? Then you need this.

In today’s issue of The Kable: Good news for Sanofi; Bad news for Gilead; The US FDA gets busy; A new call for proposals from CEPI; Disposable gastroscopes and more. Much more. Also, you may notice we’ve added sources for every story, j…

💊 UK’s NICE approves a $3 billion treatment; More bad news for Biogen; Cipla acquires more green energy stakes; Is Sanofi’s $11 billion bet beginning to pay off?

This post is for paid subscribers